期刊
EXPERT OPINION ON PHARMACOTHERAPY
卷 10, 期 11, 页码 1841-1845出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656560903048959
关键词
bupropion; naltrexone; pharmacotherapy; weight loss
Since their discovery in the brain and gastrointestinal tract nearly 40 years ago, endogenous opioid peptides have been progressively shown to play a role in the regulation of food intake. Animal and human studies regarding opioid peptides and ingestive behavior are reviewed. While the opioid receptor antagonist naltrexone is associated with minimal weight loss as monotherapy, it does have potential utility in the treatment of obesity when combined with the pro-opiomelanocortin activator bupropion.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据